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Background: The purpose of this study was to determine the yield of stereotactic core breast
biopsy and its cost-saving potential.
Methods: This observational study was conducted at the Department of Radiology at Aga Khan
Hospital in Karachi. All female patients (n = 84) undergoing stereotactic core breast biopsy
under mammographic guidance from January 2005 to May 2010 were included. Stereotactic
core biopsy was performed on a dedicated mammography unit employing a 14-gauge needle
with an automated biopsy device. Ten patients with incomplete medical records were excluded.
All breast biopsy results were either compared with surgical findings in cases of malignant
histopathological findings or with follow-up needle localization in case of benign core biopsy
findings.
Results: Fifteen of our 74 patients had malignant findings on stereotactic biopsy, confirmed on
histopathology of the final surgical mastectomy specimen. The remaining 59 patients had benign
results on histopathology; five patients had needle localization of the same area due to either
suspicious mammographic findings or clinical suspicion of malignancy. All were proven to be
histopathologically benign on open surgical biopsy. Fifty-four patients with benign results had
follow-up mammograms, and the follow-up period was 18 months to 5 years. The sensitivity
and specificity was 100%. The cost saving per patient was US$253.
Conclusion: Stereotactic core breast biopsy is a safe and cost-effective method for determining
the nature of suspicious mammographic findings.
Keywords: stereotactic, breast biopsy, BI-RADS®, mammography

Breast cancer is the most common cause of morbidity and mortality among women
worldwide.1 More than half of patients with breast cancer reside in developing
countries, where resources to fight the disease are limited.2 Most women suspected
of having breast cancer are referred for breast biopsy to determine if the lesion seen
on imaging is benign or malignant and whether further work-up and management is
warranted. Most women undergoing breast biopsy have benign lesions and do not
require further treatment. Recently published data for screening studies showed that
2616 open biopsies were performed in the UK in 2008–2009 and that 69% of these
were benign and 31% were malignant. The malignant biopsy rate has shown a decline
from 2.04 per 1000 women in 1996–1997 to 0.40 per 1000 women in 2008–2009, and
that the nonoperative diagnosis rate for cancers has increased from 63% to 95%.3
Breast biopsies may be performed by open surgery (incisional or excisional biopsy)
or by minimally invasive core needle biopsy. Core needle biopsy involves removing
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small cores of breast tissue obtained by a shallow core
needle inserted through the skin. Core needle biopsy is less
expensive, has fewer complications and a shorter recovery
time, and incurs less psychological trauma. According to a
systematic review, stereotactic-guided and ultrasonographyguided core needle biopsy procedures seem to be almost
as accurate as open surgical biopsies, and have a lower
complication rate.4
Stereotactic breast biopsy using a 14-gauge needle is a
reliable method of biopsy for nonpalpable breast lesions.5
The data suggest that 2%–4% of women undergoing
screening mammography are referred for biopsy of a mammographic abnormality.6 The majority of these patients
have benign lesions. The effort and cost involved in further
evaluation of these abnormalities is huge, and most of this
is incurred by surgical biopsies. Stereotactic breast biopsy is
a less expensive and less invasive method of breast biopsy
for evaluating mammographically detected suspicious
breast lesions.
We conducted this study to determine the yield of
stereotactic core needle biopsy for evaluation of mammographically detected nonpalpable lesions, and its effect on
cost saving for the patient.

Methods
This descriptive study was conducted in the Department of
Radiology at the Aga Khan University Hospital in Karachi
from January 2005 to May 2010. All patients (n = 84)
undergoing stereotactic breast biopsy in the department
were included. All prebiopsy mammograms were reviewed
independently by two consultant radiologists. The
mammographic findings were categorized according to the
Breast Imaging Reporting And Data System (BI-RADS®)
assessment criteria. The biopsy was performed on a
Mammomat Nova 3000 (Siemens AG, Berlin, Germany)
using an Opdima stereotactic biopsy device. A 14-gauge
needle with an automated gun was used. On average,
5–6 cores were taken. The specimens removed were
radiographed to confirm that the sample contained the
targeted suspicious microcalcifications or parenchymal
density. Ten patients with incomplete medical records
were excluded. The age of the patient, indication for
mammography, histopathological outcome, and further
management were recorded from patients’ personal files.
Concordance between the mammographic abnormality
and histopathological results was determined using Kappa
statistics. A P value ,0.05 was considered statistically
significant.
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The yield was determined by calculating the sensitivity
and specif icity of stereotactic core biopsy. The cost
comparison was done by calculating the difference between
the charges for stereotactic biopsy and open surgical biopsy
per patient.

Results
Eighty-four women underwent stereotactic core biopsy during the study period. Their mean age was 57 ± 1.3 years.
Of these, ten had incomplete medical records or follow-up
and were excluded. Of the remaining 74 women, prebiopsy
mammograms were categorized as BI-RADS II in 25 cases,
BI-RADS III in 16 cases, BI-RADS IV in 27 cases, and BIRADS V in six cases. The biopsy was performed in patients
with BI-RADS category II mammograms either because of
strong family history or a history of malignancy in the contralateral breast in order to decide on an appropriate management
plan. Similarly, in mammograms reported as BI-RADS III,
a biopsy was performed because the clinician did not want
to wait for 6 months to obtain a follow-up mammogram, to
alleviate patient anxiety, or if the clinician was concerned that
the patient would not attend the follow-up mammography.
Biopsy was performed in 23 patients to evaluate a suspicious
parenchymal density or nodule and in the rest for suspicious
microcalcifications seen on mammography. In a few patients,
a mass was clinically palpable, but the clinician opted for
image-guided biopsy as a means to target microcalcifications
in the mass. Among the patients who underwent biopsy, 15 had
malignant findings confirmed on histopathology of the final
surgical mastectomy specimen. The remaining 59 patients
had benign results on histopathology; five of these patients
had needle localization in the same area due to either suspicious mammographic findings or strong clinical suspicion of
malignancy. All were proven histopathologically to be benign
on open surgical biopsy. Fifty-four patients with benign results
on histopathology were also followed up with mammograms.
The follow-up period was 18 months to 5 years, and confirmed
benign findings. The sensitivity and specificity was 100%.
Excellent agreement was noted between mammographic
abnormality and histopathological results with a Kappa value
of 8 (P = 0.000). The cost of stereotactic core biopsy at our
institution is US$100, whereas open surgical biopsy after
needle localization costs US$353. This represents an obvious
cost saving of US$253 per patient.

Discussion
Pakistan has a higher burden of breast cancer than other
Asian countries.7,8 Image-guided breast biopsy techniques
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were developed to overcome the diagnostic problem
of increasing numbers of suspicious lesions detected
at mammography. 7 Stereotactic breast biopsy using a
14-gauge needle is an accurate method of tissue sampling
for nonpalpable breast lesions, and was used for the first
time in Sweden in 1974 for fine needle aspiration cytology.5
Improvement in techniques over the last 30 years have
allowed this method to be used to assess both palpable
and nonpalpable lesions of the breast in both screening and
symptomatic settings.9
According to most published reports, the targets for
core biopsy are all types of nonpalpable mammographic
abnormalities, including a mass, calcifications, or a calcified
mass. 10–12 The reported concordance for surgical and
stereotactic biopsy is 87%–96%.10
Our results show that 80% of all lesions biopsied were
benign, which is comparable with a study conducted by
Jackman et al.13 Recently published screening data from the
UK show that 2616 open surgical biopsies were performed
in 2008–2009, of which 69% were benign and 31% were
malignant.3
Biopsy results strongly influence the algorithm for
evaluation of suspicious lesions. The biopsy method must
be minimally invasive, accurate, and cost-effective. The
cost of stereotactic core biopsy at our institution is US$100
whereas the cost of open surgical biopsy after needle localization is US$353. This represents an obvious cost saving
of US$253 per patient.
Open surgical biopsy requires a 1-day hospital admission,
and is associated with more anxiety on the part of the patient
about undergoing a procedure in an operating room. It is also
associated with more breast scarring. In contrast, stereotactic
breast biopsy does not require hospital admission and the
entire procedure is completed in 1 hour, it is associated
with no scarring clinically or radiologically, and patients
can resume their daily activities immediately after the
procedure.
Our study showed a sensitivity of 100%, which is
comparable with that in a study conducted by Peters et al.14
In this study, all patients with benign findings on stereotactic
biopsy underwent surveillance mammography which is
routine clinical practice. No breast malignancy was missed
on surveillance mammography after 2 years of follow-up
mammography. However, the COBRA (COre Biopsy after
RAdiological localization)15 study reported a sensitivity
of 97%. In COBRA, all lesions, whether benign or malignant on stereotactic core needle biopsy, underwent open
surgical biopsy.
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Our specificity was 100% which is similar to the 99%
specificity reported by the COBRA study, in which 973
patients under went stereotactic core needle biopsy followed
by open surgical biopsy if the results of stereotactic core
needle biopsy were benign, and therapeutic surgery if the
results of stereotactic core needle biopsy were malignant.
In our study, only five patients underwent open surgical
biopsy if the results were benign, and the rest of the patients
were followed up by surveillance mammography over a
follow-up period of 18 months to 5 years.
There were a few limitations to our study. A small sample
size might have resulted in 100% sensitivity and specificity;
all patients with benign results on stereotactically guided
core needle biopsy did not undergo open surgical biopsy, and
were followed up by surveillance mammography, although
the follow-up period ranged from 18 months to 5 years.

Conclusion
Stereotactic core breast biopsy is a safe and cost-effective
method for determining the nature of suspicious finding
on mammograms. In patients with benign findings on
stereotactically guided core needle biopsy, surgical excision
is not warranted, but studies with larger numbers of patients
are needed to generalize this recommendation.
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